(RTTNews) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period, primarily reflecting a major licensing revenue from its collaboration with Swiss drug major Roche Holding AG
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.